News 
Market Data 
Discover
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Updated with the latest LOSSES:
Only if he is a fiction reader. BWVI is nothing butt a dogshit pennyscam
Just like all the other busted pennyscams you and PlowedBoi are holding heavy bags in.
Just one incredibly stoopid move - putting a Roth IRA in a pennyscam - nott to mention MRGE, Crailar, et seq.
“If shown to be successful, this delivery method could be a “holy grail” for the psychedelic space, said Mike Zapolin — aka “Zappy” — the company’s former chief visionary officer and now adviser. No toxicities, no side effects, no withdrawal. And Zapolin, who can be a little evangelical about the delivery system’s potential, believes it could work similarly for even the most highly addictive prescription drugs like benzodiazepines and opioids.”
Love it!
LOL! Some solid DD on Captain Keith's semi-retirement hobby diving funded by dunces who cannot see the obvious scam once again. Grifters like Psychoceutical insiders prey on such rockheads and suckers.. Pennyvestors are such easy marks. They will believe anything. These fools re BWVI's target audience.
Plowmaster
Thursday,September 05, 2019 4:25:08 PM
This has got to be one of the most locked float and thinnest of thin thin L2s in all of the OTC. Our day is coming quickly, treasure is coming and the cannons will BOOM! $BWVI
Plowmaster
Tuesday, September 24, 2019 11:29:51 AM
GM Toad and al treasure hunters! The fuse on the cannons are lit. Just burning down to a BOOM! $BWVI
Plowmaster
Tuesday, October 22, 2019 10:40:51 AM
BWVI absolutely has a ton going on, the quiet storm will hit a massive discovery mode soon enough. I’m happy to have been collecting treasure shares, it’s brewing and it’s coming! $BWVI
Plowmaster
Wednesday, October 23, 2019 4:57:58 PM
I keep collecting pieces of treasure shares at these levels as I can! Going to need a bigger chest soon! ;) $BWVI
Plowmaster
Tuesday, November 26, 2019 11:17:09 AM
Nice work! Looking forward to treasure and news! $BWVI
Plowmaster
Thursday, June 18, 2020 10:42:15 AM
GM toad, almost there and recovery is on! Let’s go! $BWVI
Plowmaster
Friday, June 26, 2020 9:20:50 AM
GM Toad, we about there! Get that recovery going! $BWVI
Plowmaster
Wednesday, September 09, 2020 10:00:49 PM
Wow! Great stuff!!!
Pulaski up next and along with it comes treasure! It’s happening! $BWVI
Plowmaster
Friday, September 04, 2020 9:43:57 AM
They are on the way to Pulaski. Sept looking to be a great month for BWVI! Looking forward to it! $BWVI
Perhaps the funniest aspect of your cognitive deficiency is that your posts show that you are even too dumb to realize that my references to Captain Keith is a comment about the gullible zipperheads, including you, who bleeve the nonsense this turd spews. This obvious fact goes over your head because you lack the cognitive ability to see it.
BWVI is a filthy Form 15 deregistered non-SEC reporting pennyscam. Only fools buy non-SEC registered Form 15 pennyscams retail.
So of course you hold this turd. Just like SSFT and AMFE/FUNN/FUNNQ (DOWN 97.6 percent} because you don't learn.
You have nott even learnt from the Captain Keith hobby diving scam. These pennyscams count on idiots like you bring unable to figger~OUTT the grift.
The real idiots are those assclowns who believed (and touted) Captain Keith's hobby diving pennyscam and bleeved that they would become rich frm all the treasure he recovered.
Those same idiots now bleeve in a new set of pennyscammers who do nott even have a real office.
LOL!! Stupid is as stupid does.The gullible chuckleheds who bleeved Capn Keith's bullshit now bleeve the psycho bullshit. Recalling Capn Keith and his bullshit pony show is statement bout the dumb, chuckleheads who bleeved Keith's fairly tales and now bleeve the current one.
Butt then, you bleeve a lott of nonsense - like Gro3, NSI, and "owning the supply chain" as well as junk like SSFT which was a joke also.
Very, very badd judgement and no cognition evident. You must be competing with Dealerfool for Dumbest Person to Ever Post on iHUb. You are making it a race - good luck!
I'm almost 100% confident he posts negativity to play the stock. He accumulates the dips then sells on the uptrend and when he wants to reload and play again he shows up again, trash talks and tries to do the same thing over and over. Notice how he disappeared for quite some time while this thing has bounced off that low of 7's. He'll say anything to try and convince naive people to sell the stock and feed his game. That's what I'm convinced of. Everyone has their method... I'm right there with you Big Cat, he's super annoying and will post anything to discredit any ticker.
Ultimately he's not really worth our time.
$BWVI
Psycheceutical Announces Successful First Cohort Dosing; Moves to Dose Escalation in Phase I Trial of NeuroDirect Ketamine for PTSD
MIAMI, FL / ACCESSWIRE / August 10, 2023 / Psycheceutical Bioscience, Inc. ("Psycheceutical" or the "Company") (OTC PINK:BWVI), a bioscience company dedicated to developing cutting-edge technologies for the next generation of mental health treatments, today announced the completion of dosing of the first cohort of subjects in a Phase I clinical trial of its patented NeuroDirect™ topical ketamine formulation for the treatment of Post Traumatic Stress Disorder (PTSD). NeuroDirect ketamine is the company's lead non-systemic drug candidate designed to target free nerve endings at the back of the neck, with the objective of delivering ketamine safely, effectively and without hallucinogenic effects.
Key results from first cohort include:
The topical administration of the NeuroDirect ketamine was shown to be safe and well-tolerated.
No clinically relevant adverse events or psychotomimetic effects were seen, giving the Safety Review Committee confidence to proceed with an escalation of the dosage for the second cohort. The viability of topical administration was confirmed when anticipated pharmacokinetics (PK) aligned well with the observed PK parameters in cohort 1, bolstering confidence for replication with increased dosage in cohort 2.
"We are excited about the overall success of our first cohort from our Phase I clinical trial," said Chad Harman, CEO of Psycheceutical. "The favorable safety profile for our topical NeuroDirect ketamine represents an exciting milestone in our goal of bringing to market a novel method for treating mental health and neurodegenerative diseases. We look forward to expanding our drug pipeline with other psychedelic compounds using this novel delivery method in the near future."
Psycheceutical's clinical trial program is the first ever to test the topical application of ketamine for use in treating a mental health disorder. The goal of the Phase I study, which is being conducted by iNGENu Pty Ltd. in Australia, is to test the safety, tolerability, and pharmacokinetics of NeuroDirect ketamine in 24 healthy adult participants. The company's first cohort included six trial participants who were given a topical dose of NeuroDirect ketamine and underwent a thorough safety assessment for 12 days. Topical ketamine was shown to be safe and well-tolerated for all cohort 1 participants. This data gave the trial's Safety Review Committee assertive confidence to proceed with an increased dosage for cohort 2. Full details on the clinical trial can be found here.
NeuroDirect ketamine is the first of several opportunities in the company's drug pipeline designed to treat mental health and neurodegenerative disorders. Psycheceutical's delivery technologies have been featured in numerous publications including Forbes, BioSpace, Pharmacy Times, Drug Development & Delivery, Genetic Engineering & Biotechnology News, Benzinga, and more. The company was recently named a Top 10 Biotech Startup for 2023 by Life Sciences Review. The company has attracted the attention of investors like Kevin Harrington from Shark Tank and the Chief Medical Officer is neurosurgeon Dr. Julian Bailes who was portrayed by Alec Baldwin in the movie Concussion.
https://www.accesswire.com/773524/Psycheceutical-Announces-Successful-First-Cohort-Dosing-Moves-to-Dose-Escalation-in-Phase-I-Trial-of-NeuroDirect-Ketamine-for-PTSD
nice update!
Love all the clickable information packed links in the PR! Good stuff mang! Peace Big Cat.
Psycheceutical Bioscience Announces Completion of PCAOB Audit and Future Corporation Action Strategy
Press Release | 08/01/2023 Multi-year PCAOB audited financials completed
Company on the path to become fully SEC reporting
Future corporate action with name and symbol change
MIAMI, FL / ACCESSWIRE / August 1, 2023 / Psycheceutical Bioscience, Inc. ("Psycheceutical'' or the "Company") (OTC PINK:BWVI), a bioscience company dedicated to developing cutting-edge technologies for the next generation of mental health treatments, today announced that its auditors RBSM LLP have completed a PCAOB audit of the company's financial statements for the periods ending December 31, 2022 and 2021. With the completion of the audit, Psycheceutical is well-positioned to focus on its near-term fundraising plans, to strategize its process and timing for becoming a fully reporting company with the Securities and Exchange Commission (SEC), and to advance its strategic plans for aligning its corporate name and listing symbol.
"This is a major and long-awaited milestone for our organizational strategic objectives, as this audit process has covered both pre- and post-merger periods related to our merger in 2021 with Blue Water Ventures International," stated Chad Harman, CEO of Psycheceutical. "We are eager to advance key fundraising initiatives to support our ongoing drug development efforts, including the recent start of our Phase I clinical trial in Australia to study our novel NeuroDirectTM ketamine topical to treat PTSD."
The audited financial statements can be viewed here.
PCAOB Audit Completion
The audit completion and approval by RBSM LLP, a PCAOB registered accounting and auditing firm, provides third-party verification as to the accuracy of the company's financial statements. It is expected that the audit completion and process to become a fully reporting company with the SEC will provide an enhanced sense of confidence and transparency to current and potential shareholders moving forward.
Future Name and Symbol Change
The current Blue Water Ventures International name and BWVI ticker symbol came from a reverse merger into a treasure recovery holding company, which can be confusing to investors or anyone doing due diligence. The new name and symbol is the last important step in completing the organization changeover from the merger. It is critical that current and future investors understand Psycheceutical's brand and mission to advance its patented next-generation delivery technologies for the safe and effective treatment of mental health disorders. All focus will be on bringing new therapeutics and treatment options to the market.
As Psycheceutical makes progress on its organizational strategy, it is also making strides in advancing its drug development strategy. The company recently announced the successful dosing of the first patient in the historic Phase I clinical trial for its NeuroDirect ketamine topical as a treatment for individuals suffering from PTSD. Psycheceutical's clinical trial program is the first ever to test the topical application of ketamine for use in treating a mental health disorder. As they look forward to the results of that study, the company will continue expanding its clinical trial program to other psychedelic medicines and treatment options for mental health and neurodegenerative disorders. See Psycheceutical's drug pipeline here.
About Psycheceutical Bioscience, Inc.
Psycheceutical Bioscience, Inc. (OTC PINK: BWVI) is developing cutting-edge technologies to advance the safe and effective delivery of psychedelic pharmaceutical medicines. Powered by a team of FDA drug development veterans, biotechnology experts, and top neuroscientists, Psycheceutical is on a mission to commercialize its precision dosing technologies to provide affordable, life-saving treatments to anyone suffering from mental health disorders or central nervous system diseases. Learn more at Psycheceutical.com.
Forward-Looking Statements:
Certain statements in this news release related to the Company constitute "forward-looking information" within the meaning of applicable securities laws and are prospective in nature. Forward-looking information is not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. These uncertainties include, but are not limited to, (i) general market growth for and acceptance of psychedelic-inspired medicines, (ii) capital and credit availability and market volatility, (iii) general economic conditions, (iv) governmental approvals and compliance with regulations, (v) product research and development and clinical trial risks, (vi) incorrect underlying assumptions, and (vii) our future business development, results of operations, and financial condition. These statements generally can be identified using forward-looking words such as "will," "may," "should," "could," "intend," "estimate," "plan," "anticipate," "expect," "believe," "potential" or "continue," or the negative thereof or similar variations. All information provided in this press release is as of the date of this press release, and we undertake no duty to update such information, except as required under applicable law.
Contact:
Psycheceutical Bioscience, Inc.
press@psycheceutical.com
SOURCE: Psycheceutical Bioscience, Inc.
Nice News! Multi Year Audit complete! Going Full SEC: https://www.otcmarkets.com/stock/BWVI/news/Psycheceutical-Bioscience-Announces-Completion-of-PCAOB-Audit-and-Future-Corporation-Action-Strategy?id=409451
Looking Great, love Management is sticking to the posted plan on the website, and updating it. That first in clinical after the awesome preclinical data and write up is great. Certainly optimistic where this is going!
https://psycheceutical.com/pipeline/
Awesome they are working through a faster regulatory pathway as well!
The company has already achieved important milestones in its push to commercialize its unique product, with initial discussions held with the U.S. Food and Drug Administration (FDA) where a 505(b)(2) pathway has been identified for obtaining regulatory approvals.
Love this part: Multi-Billion Dollar PTSD Market
The global PTSD treatment market size was valued at $16.0 billion in 2021 and is projected to reach $26.1 billion by 2031, growing at a compound annual growth rate (CAGR) of 4.9% (Vikita et al., 2022). With millions of people around the world suffering from PTSD, and no effective therapeutics currently available, Psychceutical's hope is that NeuroDirect ketamine could revolutionize the PTSD treatment market.
https://www.otcmarkets.com/stock/BWVI/news/First-Patient-Dosed-in-Psycheceuticals-Phase-I-Study-Exploring-Topical-Administration-of-Ketamine-to-Treat-PTSD?id=407406
$BWVI starting up clinical trials, bringing much needed medicine to the masses to combat the on going mental health crisis.
New 7/6/23: Psychedelics in the news..Australia adopts psychedelics treatment to treat PTSD & depression. Appears the word is out ..BWV$
